The Future of Neuromodulation: Insights with Dr. Daniel Blumberger
Episode Overview
ECT remains a powerful treatment despite its stigma. Newer methods like rTMS and MST offer promising alternatives with fewer side effects. Ketamine shows potential but requires further research on long-term effects. Personalised care is crucial for effective mental health treatment. The Temerty Centre is leading numerous clinical trials in neuromodulation.
It's a tremendous privilege to be able to work with these treatments and to see people's lives changed.
Join Dr. David Gratzer as he sits down with Dr. Daniel Blumberger, a leading figure in neuromodulation, to discuss the past, present, and future of this fascinating field. Dr. Blumberger shares compelling stories from his residency, like the transformation of a patient with severe depression through ECT, highlighting both the benefits and the stigma attached to this treatment.
They dive into the evolving landscape of neuromodulation, touching on newer methods like repetitive transcranial magnetic stimulation (rTMS) and magnetic seizure therapy (MST), which promise fewer side effects than traditional ECT. Dr. Blumberger also sheds light on the challenges and potential of ketamine treatments for depression, emphasising the importance of personalised care in psychiatry. With around 20 to 30 active clinical trials, the Temerty Centre for Therapeutic Brain Intervention is at the forefront of these advancements.
This episode is a must-listen for anyone interested in the cutting-edge treatments for mental health conditions. Don't miss out on this insightful conversation that could change how you view mental health treatments!